EP
JAZZ icon

Edgestream Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Edgestream Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,733
Closed -$465K – 989
2025
Q4 		$465K Buy
+2,733
New +$419K 0.01% 823
2024
Q1 		– Sell
-5,614
Closed -$691K – 920
2023
Q4 		$691K Buy
+5,614
New +$701K 0.05% 534

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Edgestream Partners's JAZZ Position: Q1 2026 in Review

Edgestream Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 2,733 shares — an estimated $465K sold.

Edgestream Partners first reported a position in JAZZ in Q4 2023 and held it in 2 quarters. The position peaked at $691K in Q4 2023. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Edgestream Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Edgestream Partners sold 2,733 Jazz Pharmaceuticals shares in Q1 2026, an estimated $465K.
  • Edgestream Partners first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Edgestream Partners's Jazz Pharmaceuticals position peaked at $691K in Q4 2023.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Edgestream Partners's 13F filing for Q1 2026, filed 18 May 2026.